Amsterdam, The Netherlands - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the US FDA has issued an Emergency Use Authorization (EUA) for Philips’ IntelliVue Patient Monitors MX750/MX850 and its IntelliVue Active Displays AD75/AD85, for use in the US during the COVID-19 health emergency . These patient monitoring solutions support infection-control protocols and remotely provide critical patient information for caregivers, capabilities that are much needed when caring for hospitalized COVID-19 patients.
Philips’ IntelliVue Patient Monitors MX750/MX850 and IntelliVue Active Displays AD75/AD85 received CE mark in 2019 and are already being used in hospitals across Europe. The EUA allows Philips to start delivering the new remote patient monitoring solution to hospitals in the US, and the company is committed to submitting a 510(k) to FDA for this acute care solution in the course of 2020.
As countries across the globe continue to combat COVID-19, while gradually resuming elective care, Philips is significantly increasing its patient monitor production to address the demand for increased Intensive Care Unit (ICU) capacity. Hospitals and health systems are increasingly relying on health technology to better manage the influx of COVID-19 patients they are seeing in Emergency Rooms (ERs) and ICUs. To minimize staff exposure to the virus that causes COVID-19 while still delivering quality care, there is a critical need for patient monitors that enable clinicians to remotely monitor a patient’s condition.